BioSpace News Archive

BiondVax Pharmaceuticals Ltd., a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, published its first quarter financial results for the quarter ended March 31, 2021.

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and other neurodegenerative disorders, announced that it has achieved enrollment target of 80 patients for its Phase 2 biomarker study of ALZ-801 in Early AD patients, who carry either one or two copies of the ε4 allele of apolipoprotein E gene.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced data from its completed Phase 1b trial evaluating the safety and tolerability of KarXT in healthy elderly volunteers.

Draupnir Bio, a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, announces the appointment of Andrew Hotchkiss as Chief Executive Officer.

Amunix Pharmaceuticals, Inc. announced that it has expanded its board of directors with the appointment of Frank Watanabe, CEO of Arcutis and a biopharmaceutical executive with extensive leadership, strategy, operations and financing experience.

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of retinal degenerative diseases, announced that its Investigational New Drug application is now open for Phase 2b clinical trial of MCO-010, an ambient-light activatable optogenetic monotherapy to restore vision in patients with advanced retinitis pigmentosa.

Omega Therapeutics, Inc. today announced the appointment of Luke Beshar to its Board of Directors.

Orum today announced the close of a $84 million Series B financing.

Glycomine, Inc. today announced that it has closed a $68 million Series B financing.

Alnylam Pharmaceuticals, Inc. , announced today that it plans to host its 8 th annual series of “RNAi Roundtable” webinars over the coming weeks.